Corona Remedies IPO 2025: Snapshot
Corona Remedies Ltd is a Gujarat-based pharmaceutical company focused on branded formulations, chronic therapies, and prescription-driven products in India. The IPO is a pure OFS of about 61.7 lakh shares, aggregating to ₹655.37 crore, with no fresh issue component.
Key IPO details for quick reference:
| Parameter | Details |
|---|---|
| IPO type | Mainboard, 100% Offer for sale. |
| Issue size | ₹655.37 crore (approx. 61.7 lakh shares) |
| Price band | ₹1,008–₹1,062 per share |
| Face value | ₹10 per share |
| Bid/issue period | 8 December 2025–10 December 2025 |
| Lot size | 14 shares per lot |
| Minimum retail investment | Around ₹14,112–₹14,868 (depending on cut-off price) |
| Allotment date (tentative) | 11 December 2025. |
| Listing date (tentative) | 15 December 2025, on NSE & BSE |
Corona Remedies IPO: Why Corona Remedies IPO Is Trending
Corona Remedies IPO is trending among investors due to its strong profit growth, high return ratios, and active grey market premium (GMP). The company reported total income of about ₹1,202 crore in FY 2024–25, up roughly 18% year-on-year, while profit after tax (PAT) surged by around 65% to ₹149.43 crore.
Key reasons for buzz:
- The company experienced double-digit revenue growth, accompanied by faster profit expansion.
- The company achieved a strong return on capital employed (ROCE) of about 41% in FY25, indicating highly efficient capital usage.
- Over the past few years, the company has maintained healthy EBITDA margins of approximately 20–21%.
Corona Remedies IPO: Dates, Price Band, and Lot Size
Understanding the timeline and investment amounts is crucial for high-intent IPO investors.
- Corona Remedies IPO date:
8–10 December 2025 - Corona Remedies IPO price band:
₹1,008–₹1,062 per equity share - Corona Remedies IPO lot size:
14 shares per lot.
Approximate investment requirements for different categories:
- Retail (1 lot):
about ₹14,112–₹14,868 - Retail (max 13 lots):
around ₹1.8–₹1.9 lakh - Small HNI (S-HNI, 14 lots):
about ₹2.0–₹2.1 lakh - Big HNI (bNII, 68 lots):
about ₹10 lakh+
Corona Remedies IPO GMP Today: IPO GMP and expectations for listing gains are discussed.
Several market trackers report a strong grey market premium (GMP) in the ₹300+ range over the upper price band, indicating robust listing expectations. A high and stable Corona Remedies IPO GMP generally suggests strong demand and potential listing gains, though it is unofficial and highly volatile.
Actionable tips for using GMP data:
- Track the Corona Remedies IPO GMP trend for 3–4 days before the issue opening.
- Focus on direction (rising or falling) rather than absolute GMP alone.
- Avoid over-leveraging solely based on grey market signals; combine with fundamentals.
Company Overview and Business Model
Corona Remedies mainly focuses on branded generic and specialty pharmaceutical products, particularly in areas like heart health, diabetes, and other lifestyle-related treatments. The company distributes largely through doctors’ prescriptions, field-force marketing, and a strong pan-India network.
Business strengths that appeal to IPO investors:
- The company’s diversified product portfolio, which includes both chronic and sub-chronic therapies, typically ensures more stable and recurring demand.
- The company has expanded its reach into metros and Tier-II/III cities, thereby mitigating the risk of geographic concentration.
- Focus on branded play rather than pure commodity generics, allowing relatively better margins.
Financial Performance: Revenue, Profit, Margins, and ROCE
Strong financials are a core reason many investors are searching for the Corona Remedies IPO review and Corona Remedies IPO fundamentals.
Key recent financials (₹ crore):
- FY23 total income:
about ₹891 crore; PAT: ~₹84.9 crore - FY24 total income:
about ₹1,021 crore; PAT: ~₹90.5 crore - FY25 total income:
about ₹1,202 crore; PAT: ~₹149.4 crore
Quality metrics:
- EBITDA margin:
around 20–21% recently. - ROCE:
The projected ROCE is around 41% in FY25, which places the company among high-ROCE pharma players. - The company’s net worth exceeds ₹600 crore, and its moderate borrowings indicate a comfortable balance sheet.
For investors screening IPOs using fundamentals, Corona Remedies scores well on growth, profitability, and capital efficiency.
Key Risks in Corona Remedies IPO
Even with attractive metrics, a balanced Corona Remedies IPO analysis must consider risks.
Main risk factors:
- Regulatory risk:
Pharma is tightly regulated; any compliance issues with Indian or overseas regulators could impact operations. - Pricing pressure:
Government price controls and intense competition in generics can squeeze margins. - OFS structure:
Since the IPO is a 100% OFS, no fresh capital enters the company; proceeds go to selling shareholders, which some long-term investors may view less favorably.
Actionable takeaway: Use these risks to size the position conservatively and avoid overexposure, especially if applying purely for listing gains.
Should You Apply for the Corona Remedies IPO?
Whether to apply depends on risk appetite, time horizon, and portfolio allocation strategy.
The Corona Remedies IPO may suit:
- Investors may find the Corona Remedies IPO appealing if they seek exposure to a mid-sized, branded pharma player with strong ROCE and consistent margins.
- Short-term traders aiming for possible listing gains supported by a healthy Corona Remedies IPO GMP and positive sentiment.
It may not suit:
- Ultra-conservative investors who have a preference for large-cap, low-volatility stocks may not find this approach suitable.
- Investors are uncomfortable with OFS-only structures where no new funds are infused in the company.
A disciplined approach is to cap allocation per IPO (for example, 5–10% of your equity portfolio in total IPO exposure) and diversify across sectors.
How to Apply for Corona Remedies IPO Online
Applying online is straightforward through most discount and full-service brokers.
Basic steps for applying:
- Log in to your broker’s app or net-banking portal that supports ASBA.
- Search for Corona Remedies IPO and select the issue.
- Choose the investor category (Retail/HNI), select the cut-off price for simplicity, and enter the number of lots.
- Please confirm the UPI mandate or ASBA block request in your bank app.
For a practical walk-through, refer to your broker’s IPO help section or NSE/BSE investor education pages.
Actionable IPO Investing Tips for Readers
To keep readers engaged and encourage long page visits, include clear, practical advice they can immediately apply:
- Always read the RHP (Red Herring Prospectus) and check the revenue mix, top products, and dependency on a few brands.
- Compare Corona Remedies’ margins, ROCE, and valuation multiples with listed mid-cap pharma peers before subscribing.
- Avoid applying for every IPO; build a watchlist and prioritize those with strong fundamentals plus reasonable valuations.
- After the IPO listing, investors should establish a clear exit or holding strategy, such as booking partial profits on significant gains while retaining the remaining shares if the company’s fundamentals remain strong.
Internal and External Links
Within your site, you can internally link this article to:
- A detailed guide on “How to analyze pharma IPOs using financial ratios”
- A step-by-step tutorial: “How to apply for IPOs using UPI and ASBA”
- A recent post on another issue, such as “Vidya Wires IPO review” or “Meesho IPO: long-term vs. listing gain strategy”
For an authoritative external source, link to the SEBI or NSE/BSE IPO section where investors can download the official RHP and check live issue data.
READ MORE: Zuari Agro Chemicals Buy Recommendation 2025: ₹660 Target & Strategy
Conclusion: Is Corona Remedies IPO a Buy?
Corona Remedies IPO combines strong profit growth, high ROCE, stable margins, and positive grey market sentiment, making it an attractive candidate on many IPO shortlists. However, the OFS-only structure, sector competition, and regulatory risks mean investors should size their bets prudently and treat this as part of a diversified strategy rather than an all-or-nothing opportunity.
Encourage readers to bookmark this post, explore your other IPO reviews, and follow your latest market calls so they can stay updated on subscription numbers, GMP trends, and any last-minute changes before the Corona Remedies IPO listing.
